Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 132

1.

Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy".

Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S.

Sarcoma. 2019 Aug 27;2019:7608743. doi: 10.1155/2019/7608743. eCollection 2019.

2.

The Fontan Thromboprophylaxis Dilemma: To Give, or What Not to Give.

Chugh R.

J Am Coll Cardiol. 2019 Aug 27;74(8):1082-1085. doi: 10.1016/j.jacc.2019.07.021. No abstract available.

PMID:
31439218
3.

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).

Widemann BC, Lu Y, Reinke D, Okuno SH, Meyer CF, Cote GM, Chugh R, Milhem MM, Hirbe AC, Kim A, Turpin B, Pressey JG, Dombi E, Jayaprakash N, Helman LJ, Onwudiwe N, Cichowski K, Perentesis JP.

Sarcoma. 2019 Jul 24;2019:7656747. doi: 10.1155/2019/7656747. eCollection 2019.

4.

Use of the facial artery-based cutaneous island flap (melo-labial flap) for reconstruction of the neopharynx following total laryngectomy: a novel technique.

Gupta DK, Chugh R, Singh SK, Pati S.

BMJ Case Rep. 2019 Aug 4;12(8). pii: e230712. doi: 10.1136/bcr-2019-230712.

PMID:
31383687
5.

Nonalcoholic Fatty Liver Disease: The Overlooked Complication of Type 2 Diabetes.

Akshintala D, Chugh R, Amer F, Cusi K.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2019 Jul 9.

6.

Correction: Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.

Banerjee S, Sangwan V, McGinn O, Chugh R, Dudeja V, Vickers SM, Saluja AK.

J Biol Chem. 2019 Jul 5;294(27):10739. doi: 10.1074/jbc.AAC119.009844. No abstract available.

7.

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.

Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG.

Cancer. 2019 Jul 15;125(14):2445-2454. doi: 10.1002/cncr.32084. Epub 2019 Apr 29.

8.

Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases.

Siontis BL, Zhao L, Leja M, McHugh JB, Shango MM, Baker LH, Schuetze SM, Chugh R.

Sarcoma. 2019 Mar 10;2019:1960593. doi: 10.1155/2019/1960593. eCollection 2019.

9.

Successful embryo cryopreservation immediately following a full-term delivery in a woman with newly diagnosed Ewing's sarcoma.

Giuliani E, Ellman EM, Chugh R, Moravek MB.

J Assist Reprod Genet. 2019 May;36(5):1023-1028. doi: 10.1007/s10815-019-01445-6. Epub 2019 Apr 5. No abstract available.

PMID:
30953232
10.

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM.

Ann Oncol. 2019 Feb 5. doi: 10.1093/annonc/mdy557. [Epub ahead of print] No abstract available.

PMID:
30726873
11.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices.

Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL.

JAMA Oncol. 2019 Apr 1;5(4):497-505. doi: 10.1001/jamaoncol.2018.6437. Erratum in: JAMA Oncol. 2019 Mar 7;:.

PMID:
30653226
12.

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.

Smith DC, Chugh R, Patnaik A, Papadopoulos KP, Wang M, Kapoun AM, Xu L, Dupont J, Stagg RJ, Tolcher A.

Invest New Drugs. 2019 Aug;37(4):722-730. doi: 10.1007/s10637-018-0714-6. Epub 2018 Dec 28.

13.

Canonical Wnt/β-catenin signaling activation in soft-tissue sarcomas: A comparative study of synovial sarcoma and leiomyosarcoma.

Briski LM, Thomas DG, Patel RM, Lawlor ER, Chugh R, McHugh JB, Lucas DR.

Rare Tumors. 2018 Nov 25;10:2036361318813431. doi: 10.1177/2036361318813431. eCollection 2018.

14.

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.

Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S.

Sarcoma. 2018 Oct 24;2018:2068517. doi: 10.1155/2018/2068517. eCollection 2018. Erratum in: Sarcoma. 2019 Aug 27;2019:7608743.

15.

Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone.

Mason JW, Chugh R, Patel A, Gutte R, Bhatia A.

Clin Transl Sci. 2019 Jan;12(1):47-52. doi: 10.1111/cts.12594. Epub 2018 Nov 27.

16.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC.

Invest New Drugs. 2019 Jun;37(3):461-472. doi: 10.1007/s10637-018-0665-y. Epub 2018 Sep 19.

PMID:
30229512
17.

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.

Mir O, Azaro A, Merchan J, Chugh R, Trent J, Rodon J, Ohnmacht U, Diener JT, Smith C, Yuen E, Oakley GJ 3rd, Le Cesne A, Soria JC, Benhadji KA, Massard C.

Eur J Cancer. 2018 Nov;103:88-97. doi: 10.1016/j.ejca.2018.08.012. Epub 2018 Sep 12.

PMID:
30218977
18.

Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Patel A, Chavan R, Yeole R, Friedland HD, Bhatia A.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00682-18. doi: 10.1128/AAC.00682-18. Print 2018 Aug.

19.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.

JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601.

20.

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Coccia PF, Pappo AS, Beaupin L, Borges VF, Borinstein SC, Chugh R, Dinner S, Folbrecht J, Frazier AL, Goldsby R, Gubin A, Hayashi R, Huang MS, Link MP, Livingston JA, Matloub Y, Millard F, Oeffinger KC, Puccetti D, Reed D, Robinson S, Rosenberg AR, Sanft T, Spraker-Perlman HL, von Mehren M, Wechsler DS, Whelan KF, Yeager N, Gurski LA, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):66-97. doi: 10.6004/jnccn.2018.0001.

PMID:
29295883

Supplemental Content

Support Center